Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children6210.24287/1726-1708-2017-16-3-7-14СтатьиThe results of pilot trial ALL-REZ-MВ-2014 for children with relapsed acute lymphoblastic leukemiaРезультаты противорецидивной терапии острого лимфобластного лейкоза у детей по пилотному протоколу ALL-REZ-MВ-2014https://orcid.org/0000-0002-8725-7532DyakonovaYu. Yu.ДьяконоваЮ. Ю.
Russian Federation

MD, hematologist. Department of information technologies’ development

Russia 117997, Moscow, Samory Mashela st., 1

врач-гематолог отделения онкогематологии

117997, Москва, ГСП-7, ул. Саморы Машела, 1

Yuliya.Dyakonova@fcchomoscow.ruBydanovO. I.БыдановО. И.
Russian Federation

Moscow

Minsk, Republic of Belarus

https://orcid.org/0000-0002-4779-1896MyakovaN. V.МяковаН. В.
Russian Federation
AbugovaYu. G.АбуговаЮ. Г.
Russian Federation
https://orcid.org/0000-0003-0143-1921AleynikovaO. V.АлейниковаО. В.
Russian Federation
ArakayevO. R.АракаевО. Р.
Russian Federation
BoychenkoE. G.БойченкоЭ. Г.
Russian Federation
DubrovinaM. E.ДубровинаМ. Э.
Russian Federation
YevstratovD. A.ЕвстратовД. А.
Russian Federation
LitvinovD. V.ЛитвиновД. В.
Russian Federation
OlshanskayaYu. V.ОльшанскаяЮ. В.
Russian Federation
PonomarevaN. I.ПономареваН. И.
Russian Federation
PopovA. M.ПоповА. М.
Russian Federation
PotapenkoL. A.ПотапенкоЛ. А.
Russian Federation
RogovA. V.РоговА. В.
Russian Federation

Stavropol

RumyantsevaYu. V.РумянцеваЮ. В.
Russian Federation
FominykhV. V.ФоминыхВ. В.
Russian Federation
KhachatryanL. A.ХачатрянЛ. А.
Russian Federation
KarachunskyA. I.КарачунскийА. И.
Russian Federation
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, МоскваDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation Republican Research Center for Pediatric Oncology, Hematology and ImmunologyРеспубликанский научно-практический центр детской гематологии и онкологии Минздрава РБ, Минск, Республика БеларусьФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, МоскваDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, МоскваRepublican Research Center for Pediatric Oncology, Hematology and ImmunologyРеспубликанский научно-практический центр детской гематологии и онкологии Минздрава РБ, Минск, Республика БеларусьRegional Children's Hospital № 1Областная детская клиническая больница № 1, Екатеринбург1 Children's hospitalДетская городская больница № 1, Санкт-ПетербургDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, МоскваRussian Children's Clinical HospitalФГБУ «Российская детская клиническая больница» Минздрава России, МоскваDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, МоскваPediatric oncology and hematology of the Reginal Children's HospitalКраевая детская клиническая больница, СтавропольDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, Москва1008201716371410082018Copyright ©; 2017, «D. Rogachev NMRCPHOI»Copyright ©; 2017, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2017«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/62

The relapse of acute lymphoblastic leukemia (ALL) in children is still a difficult task. This is due both to the difficulties of achieving a second remission and to the problems of organizing allogeneic bone marrow  transplantation (BMT) in those patients who need it. The standard approach is the use of second-line drugs  in the regime of high-dosage chemotherapy blocks, but the response rate for this treatment in patients with  early relapses remains low and the response time is short. Recently, new drugs with different  mechanisms of action have appeared that can give an opportunity for a full remission. The organization of a multicentre study on anti-relapse therapy in the Russian Federation is an urgent task, the solution of which  can help in studying new approaches to therapy and in the organization of BMT logistics. This article  presents the results of a pilot multicentre study on the treatment of relapses of ALL in children in the  Russian Federation. The effectiveness of standard therapy for a group with late relapses and the efficacy and toxicity of interventional blocks with the use of bortezomib, clofarabine, nelarabine are presented.

acute lymphoblastic leukemiarelapsechildrenострый лимфобластный лейкозрецидивдетилечение1. Bhatla T., Jones C.L., Meyer J.A., Vitanza N.A., Raetz E.A., Carroll W.L. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. J Ped Hematol/Oncol 2014; 36 (6): 413-8.Bhatla T., Jones C.L., Meyer J.A., Vitanza N.A., Raetz E.A., Carroll W.L. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. J Ped Hematol/Oncol 2014; 36 (6): 413-8.2. Eckert C., von Stackelberg A., Seeger K., Groeneveld .TW., Peters C., Klingebiel T., et al. Minimal residual desease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - Long-term results of trial ALL-REZ P95/96. Eur J Cancer 2013; 49 (6): 1346-55.Eckert C., von Stackelberg A., Seeger K., Groeneveld .TW., Peters C., Klingebiel T., et al. Minimal residual desease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - Long-term results of trial ALL-REZ P95/96. Eur J Cancer 2013; 49 (6): 1346-55.3. Einsiedel H.G., von Stackelberg A., Hartmann R., Fengler R., Schrappe M., Janka-Schaub G., et al. Long-term outcome in children with relapse ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005; 23: 7942-50.Einsiedel H.G., von Stackelberg A., Hartmann R., Fengler R., Schrappe M., Janka-Schaub G., et al. Long-term outcome in children with relapse ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005; 23: 7942-50.4. Bailey L.C., Lange B.J., Rheingold S.R., Bunin N.J. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol 2008; 9; 873-83.Bailey L.C., Lange B.J., Rheingold S.R., Bunin N.J. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol 2008; 9; 873-83.5. Henze G., von Stackelberg A., Eckert C. ALL-REZ BFM - The consecutive Trials for children with relapse Acute Lymphoblastic Leukemia. Clin Padiatr 2013; 225 (1): S73-S78.Henze G., von Stackelberg A., Eckert C. ALL-REZ BFM - The consecutive Trials for children with relapse Acute Lymphoblastic Leukemia. Clin Padiatr 2013; 225 (1): S73-S78.6. Tallen G., Ratei R., Mann G., Kaspers G., Niggli F., Karachunsky A., et al. Long-term outcome in children with relapse acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified shot-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Оncol 2010; 28 (14): 2339-47.Tallen G., Ratei R., Mann G., Kaspers G., Niggli F., Karachunsky A., et al. Long-term outcome in children with relapse acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified shot-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Оncol 2010; 28 (14): 2339-47.7. Szczepanek J., Pogorzala M., Konatkowska B., et al. Differntial ex vivo activity of bortesomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukemia. J Anticancer Res 2010; Jun; 30 (6): 2119-24.Szczepanek J., Pogorzala M., Konatkowska B., et al. Differntial ex vivo activity of bortesomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukemia. J Anticancer Res 2010; Jun; 30 (6): 2119-24.8. Bertaina A., Vinti L., Stroccio L., et al. The combination of bortezomib with chemotherapy to treat relapse/refractory acute lymphoblastic leukemia of chailhood. Br J Haematol 2017; Feb; 176 (4): 629-36.Bertaina A., Vinti L., Stroccio L., et al. The combination of bortezomib with chemotherapy to treat relapse/refractory acute lymphoblastic leukemia of chailhood. Br J Haematol 2017; Feb; 176 (4): 629-36.9. Hijiya N., Gaynon P., Barry E., Silverman L., Thomson B., Chu R., et al. A multicenter phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009; 23 (12): 2259-64.Hijiya N., Gaynon P., Barry E., Silverman L., Thomson B., Chu R., et al. A multicenter phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009; 23 (12): 2259-64.10. Hijiya N., Thomson B., Isakoff M.S., Silverman L.B., Steinherz P.G., Borowitz M.J., et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011; 118 (23): 6043-9.Hijiya N., Thomson B., Isakoff M.S., Silverman L.B., Steinherz P.G., Borowitz M.J., et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011; 118 (23): 6043-9.11. Cohen M.H., Johnson J.R., Justice R., Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncolog 2008; 13 (6): 709-14.Cohen M.H., Johnson J.R., Justice R., Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncolog 2008; 13 (6): 709-14.12. Kurtzberg J., Ernst T.J., Keating M.J., Gandhi V., Hodge J.P., Kisor D.F., et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005; 23 (15): 3396-403.Kurtzberg J., Ernst T.J., Keating M.J., Gandhi V., Hodge J.P., Kisor D.F., et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005; 23 (15): 3396-403.